13395-02-3
Chemical Structure
Aristolactam I
Synonym(s): Aristololactam; Aristolactam
- CAS. Nr.: 13395-02-3
- Formula:C17H11NO4
- Molecular Weight:293.27
IUPAC Name: 8-methoxy-[1,3]dioxolo[4',5':4,5]benzo[1,2,3-cd]benzo[f]indol-5(6H)-one
InChIKey: MXOKGWUJNGEKBH-UHFFFAOYSA-N
SMILES: O=C1NC2=C(C3=C4C(C(OC)=CC=C4)=C2)C1=CC5=C3OCO5
Biological Activity: Aristolactam I is an AQP1 inhibitor and Aristolochic acid I metabolite. Aristolactam I can be isolated from Aristolochia plants. Aristolactam I downregulates Twist1 expression, increases E-cadherin expression, and activates the TGF-β/Smad signaling pathway. Aristolactam I has anticancer activity against breast cancer. Aristolactam I is nephrotoxic. Aristolactam I is mainly used in the study of breast cancer and kidney diseases such as renal interstitial fibrosis[1][2][3][4][5].
| Art. -Nr. | Produktname | Reinheit | Beschreibung | Pricing | |||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
|
Aristolactam I | 99.44% | Aristolactam I is an AQP1 inhibitor and Aristolochic acid I metabolite. Aristolactam I can be isolated from Aristolochia plants. Aristolactam I downregulates Twist1 expression, increases E-cadherin expression, and activates the TGF-β/Smad signaling pathway. Aristolactam I has anticancer activity against breast cancer. Aristolactam I is nephrotoxic. Aristolactam I is mainly used in the study of breast cancer and kidney diseases such as renal interstitial fibrosis. | ||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
|
|
Aristolactam I (Standard) | ≥98% | Aristolactam I (Standard) is the analytical standard of Aristolactam I. This product is intended for research and analytical applications. Aristolactam I is an AQP1 inhibitor and Aristolochic acid I metabolite. Aristolactam I can be isolated from Aristolochia plants. Aristolactam I downregulates Twist1 expression, increases E-cadherin expression, and activates the TGF-β/Smad signaling pathway. Aristolactam I has anticancer activity against breast cancer. Aristolactam I is nephrotoxic. Aristolactam I is mainly used in the study of breast cancer and kidney diseases such as renal interstitial fibrosis. | ||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
References
- [1]. Lee S, et al. Aristolactam I inhibits cell migration and invasion through regulation of Twist1 in MDA‐MB‐231 breast cancer cells. Bulletin of the Korean Chemical Society, 2022, 43(9): 1148-1151.
- [2]. Zhang X, et al. An investigation on nephrotoxicity of Aristolactam I induced epithelial-mesenchymal transition on HK-2 cells. Toxicon. 2021 Oct 15;201:21-26. [Content Brief]
- [3]. Li J , et al. Toxicities of aristolochic acid I and aristololactam I in cultured renal epithelial cells. Toxicol In Vitro. 2010 Jun;24(4):1092-7. [Content Brief]
- [4]. Zhou Y , et al. Mitochondrial uptake of aristolactam I plays a critical role in its toxicity. Toxicol Lett. 2024 Apr;394:76-91. [Content Brief]
- [5]. Li J, et al. Expression of Renal Aquaporins in Aristolochic Acid I and Aristolactam I-Induced Nephrotoxicity. Nephron. 2016;133(3):213-21. [Content Brief]
